Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition of notoginsen triterpenes and tanshinone IIA sodium sulfonate

A technology of Panax notoginseng saponins and composition, which is applied in the field of medicine to achieve the effects of high drug purity, avoiding drug loss, and simple preparation process

Inactive Publication Date: 2007-03-14
SHANDONG XUANZHU PHARMA TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Currently using Panax notoginseng saponins and Tanshinone II A The interaction of sodium sulfonate and the compatibility of prescriptions to treat cardiovascular and cerebrovascular diseases have not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of notoginsen triterpenes and tanshinone IIA sodium sulfonate

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0018] Experimental example 1: Panax notoginseng saponins and tanshinone II A Study on the efficacy of sodium sulfonate in combination with medication

[0019] Test animals: mice, male, weighing 22±8g, 250 in number, 10 in each group.

[0020] The mice were observed for one week in a breeding and observation room, the temperature of the observation room was 20±3°C, the relative humidity was 30-70%, and the light was 12 hours. The test animals were randomly divided into 25 groups.

[0021] Test product: Panax notoginseng saponins, commercially available, the content should not be less than 55.0%;

[0022] Tanshinone II A Sodium sulfonate, commercially available, the content should not be less than 97.0%;

[0023] Panax notoginseng saponins injection: 150mg;

[0024] Tanshinone II A Sodium sulfonate injection: 40mg;

[0025] Panax notoginseng saponins and tanshinone II A Sodium sulfonate compatibility injection, self-made;

[0026] See Tabl...

experiment example 2

[0032] Experimental example 2: anti-platelet aggregation effect

[0033] Experimental animals: rats, 60, weighing 200g±10g;

[0034] Test product: Panax notoginseng saponins, commercially available, the content should not be less than 55.0%;

[0035] Tanshinone II A Sodium sulfonate, commercially available, the content should not be less than 97.0%;

[0036] Panax notoginseng saponins injection: 150mg;

[0037] Tanshinone II A Sodium sulfonate injection: 40mg;

[0038] Composition injection 1: self-made, Panax notoginseng saponins: Tanshinone II A Sulfonic acid=120:12mg;

[0039] Composition injection 2: self-made, Panax notoginseng saponins: Tanshinone II A Sulfonic acid=120:30mg;

[0040] Composition injection 3: self-made, Panax notoginseng saponins: Tanshinone II A Sulfonic acid=120:240mg.

[0041] Experimental method: Rats were randomly divided into 6 groups, 10 in each group, respectively control group, Panax notoginseng sapo...

experiment example 3

[0047] Experimental Example 3: Effects on Experimental Arterial Thrombosis in Rats

[0048] Experimental animals: Wistar rats, 40, weighing 200g±10g;

[0049] Test product: Composition injection, self-made, combining Panax notoginseng saponins and Tanshinone II A Sodium sulfonate (calculated as dry product, containing C 19 h 17 NaO 6 S not less than 97.0%) were formulated into composition 1, composition 2 and composition 3 according to the weight ratio of 1:0.1, 1:0.25 and 1:2 respectively.

[0050] Experimental method: Wistar rats were taken and randomly divided into groups according to body weight, with 10 rats in each group. The rats in the control group were intravenously injected with physiological saline; the administration group was intravenously injected with 2 mg / kg of the composition injection. During the experiment, intraperitoneal injection of 20% urethane 1g / kg was anesthetized, the supine position was fixed, and the common carotid artery was separated. The s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy, wherein a composition including the active constituents of notoginsen triterpenes and tanshinone IIA or pharmaceutically acceptable salts is disclosed, the invention also discloses the preparation containing the pharmaceutical composition and its preparing process, the composition can be made into clinically and pharmaceutically acceptable dose forms including oral liquids or injections.

Description

[technical field] [0001] The invention belongs to the technical field of medicine, and relates to a composition consisting of Panax notoginseng saponins and Tanshinone II containing medicinal components. A A pharmaceutical composition or a pharmaceutically acceptable salt thereof, a preparation containing the pharmaceutical composition and a preparation method thereof. [Background technique] [0002] Cardiovascular and cerebrovascular diseases such as stroke, coronary heart disease, and angina pectoris are one of the main causes of human death. According to the report of the World Health Organization, the mortality rate of cardiovascular diseases in the world accounted for 29% of the total mortality rate in 1990, ranking second. In 1994 The number of deaths worldwide is 52.2 million in 2000, of which 15.3 million died of cardiovascular diseases, while in 1999 the number of deaths from cardiovascular diseases in the world was 16.97 million, accounting for 30.3% of the total ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/258A61P9/10A61K31/343
Inventor 蔡军
Owner SHANDONG XUANZHU PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com